Ross G. Clark
Keine laufenden Positionen mehr
Profil
Ross G.
Clark has been Chief Technical Officer of Tercica, Inc. since May 2002 and a Director since December 2001.
From December 2001 to August 2003, he was Chairman of Tercica and Chief Executive Officer and President from December 2001 to February 2002.
Dr. Clark founded Tercica Limited in September 2000 and has been Professor of Endocrinology at the University of Auckland since September 1997.
From October 1997 to January 2000, he was Chief Scientist of NeuronZ Limited and was appointed a Director of ViaLactia Biosciences (NZ) Ltd.
in July 1999.
From 1990 to 1997, Dr. Clark was Senior Scientist of Genentech, Inc. He received a BS degree, a Dip.Sci.
and a PhD in Veterinary Physiology from Massey University.
Ehemalige bekannte Positionen von Ross G. Clark
| Unternehmen | Position | Ende |
|---|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Technik-/Wissenschafts-/F&E-Leiter | 21.06.2008 |
| Auckland University | Corporate Officer/Principal | 21.06.2008 |
| NeuronZ Ltd. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2000 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1997 |
| ViaLactia Biosciences (NZ) Ltd. | Direktor/Vorstandsmitglied | - |
Ausbildung von Ross G. Clark
| Massey University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
| Tercica Ltd. | |
| NeuronZ Ltd. | |
| ViaLactia Biosciences (NZ) Ltd. | |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
